- Home
- Life Sciences
- Pharmaceutical
- Pathology
- Pathology Analysis & Statistics, May 2013
Talk to Alison
(866) 682 9815
Search inside this page
Top countries
- United States (3 964)
- World (2 455)
- Japan (569)
- France (2 545)
- Germany (438)
-
- Spain (416)
- United Kingdom (2 502)
- Europe (548)
- Italy (416)
- China (165)
- India (127)
- Canada (2 196)
- Australia (2 157)
- Sweden (43)
- Denmark (31)
- South Korea (2 355)
- Norway (10)
- Singapore (2 167)
- Switzerland (25)
- Indonesia (9)
Publication dates
Publishers
- Global Data (1 525)
- Global Markets Direct (1 838)
- Bioseeker (243)
- Euromonitor International (26)
- BCC Research (41)
-
- Ibisworld (8)
- Daedal Research (2)
- Firstword Pharma (7)
- GBI Research (41)
- KnowMade (2)
- World Market Intelligence Ltd (18)
- Asianet-Pakistan (4)
- Currentpartnering (97)
- Global Industry Analysts (1)
- International Market Analysis Research and Consult (11)
- La Merie Publishing (31)
- MarketLine (41)
- Transparency Market Research (1)
- TriMark Publications (7)
- Business Monitor International (17 314)
- Datamonitor (316)
- Life Science Analytics (LSA) (61)
- Global Research & Data Services (55)
- ICD Research (47)
- Frost & Sullivan (44)
- Timely Data Resources Inc. (41)
- Visiongain (32)
- Global Industry Analyst (28)
- Espicom Business Intelligence (27)
- Business Review (23)
- ABMRG (22)
- The Assessment Group (19)
- Kalorama Information (17)
- SCRIP Insights (17)
- Koncept Analytics (15)
- Asia Market Information & Development Company (14)
- CHI Insight Pharma Reports (14)
- Apollo Managed Care Consultants (13)
- Infiniti Research Limited (9)
- Sociable Pharma (9)
- IData Research, Inc. (9)
- Grey House Publishing (7)
- RNCOS (6)
- BioPharm Reports (5)
- MarketsandMarkets (5)
- Venture Planning Group (5)
- Aruvian's R'search (4)
- Freedonia (4)
- Canadean Ltd (3)
- Netscribes (India) Pvt. Ltd. (3)
- Renub Research (3)
- Arrowhead (2)
- France Innovation Scientifique et Transfert (2)
- Greystone Research Associates (2)
- Packaged Facts (2)
- Urch Publishing (2)
- Barnes Reports (1)
- Cygnus Business Consulting and Research (1)
- Ken Research Private (1)
- PMR Ltd. (1)
- Red Mountain Insights (1)
- Research In China (1)
- VacZine Analytics Group Of Assay Advantage Ltd (1)
- Verdict Research Ltd (1)
- WinterGreen Research (1)
- Zzz FACT Research (1)
All regions
-
- Armenia (1)
- Azerbaijan (2)
- Bangladesh (2)
- China (165)
- Georgia (7)
- India (127)
- Indonesia (9)
- Iran (1)
- Israel (28)
- Japan (569)
- Jordan (2)
- Kazakhstan (2)
- Kyrgyz Republic (kyrgyzstan) (1)
- Lebanon (2)
- Malaysia (4)
- North Korea (119)
- Oman (1)
- Pakistan (7)
- Philippines (12)
- Qatar (1)
- Saudi Arabia (7)
- Singapore (2 167)
- South Korea (2 355)
- Taiwan (19)
- Thailand (12)
- Turkey (5)
- United Arab Emirates (2)
- Vietnam (3)
-
- Austria (10)
- Belgium (16)
- Bulgaria (2)
- Croatia (2)
- Cyprus (2)
- Czech Republic (6)
- Denmark (31)
- Estonia (1)
- Finland (7)
- France (2 545)
- Germany (438)
- Greece (13)
- Hungary (6)
- Ireland (15)
- Italy (416)
- Latvia (1)
- Lithuania (1)
- Luxembourg (1)
- Macedonia (1)
- Moldova, Republic Of (1)
- Netherlands (26)
- Norway (10)
- Poland (14)
- Portugal (5)
- Romania (6)
- Russian Federation (27)
- Serbia and Montenegro (1)
- Slovakia (slovak Republic) (3)
- Slovenia (3)
- Spain (416)
- Sweden (43)
- Switzerland (25)
- Ukraine (3)
- United Kingdom (2 502)
-
- Argentina (19)
- Australia (2 157)
- Brazil (2 439)
- Canada (2 196)
- China (165)
- France (2 545)
- Germany (438)
- India (127)
- Indonesia (9)
- Italy (416)
- Japan (569)
- Mexico (32)
- Russian Federation (27)
- Saudi Arabia (7)
- South Africa (17)
- South Korea (2 355)
- Turkey (5)
- United Kingdom (2 502)
- United States (3 964)
-
- Australia (2 157)
- Austria (10)
- Belgium (16)
- Canada (2 196)
- Chile (3)
- Czech Republic (6)
- Denmark (31)
- Estonia (1)
- Finland (7)
- France (2 545)
- Germany (438)
- Greece (13)
- Hungary (6)
- Ireland (15)
- Israel (28)
- Italy (416)
- Japan (569)
- Luxembourg (1)
- Mexico (32)
- Netherlands (26)
- New Zealand (6)
- Norway (10)
- Poland (14)
- Portugal (5)
- Slovenia (3)
- South Korea (2 355)
- Spain (416)
- Sweden (43)
- Switzerland (25)
- Turkey (5)
- United Kingdom (2 502)
- United States (3 964)
data types
Free Market Research Guides to Download
Pathology Analysis & Statistics, May 2013
You might be interested in: cancer, breast cancer, prostate cancer, more »
» Purchase Premium Reports
1-40 of about 4 800 reports
Analytical Tool - Hematological Cancers
- $ 8 925
- Industry report
- April 2013
- by Bioseeker
"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...
- Industries : Pathology
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Viviant/Combriza (Osteoporosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Spain, Italy, Japan, United States, World
Evista (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : United States, World, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Aprela (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Aprela (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Aprela (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : United States, World, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Ostora (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Ostora (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Ostora (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Japan, China
Recalbon/Bonoteo (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Recalbon/Bonoteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Recalbon/Bonoteo (Osteoporosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Japan, United States, World
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Romosozumab (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : France, World, Spain, Italy, Germany, Japan, India, China, Europe, United States, United Kingdom
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Europe, United Kingdom
Actonel (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Actonel (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Actonel (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
- $ 5 995
- Industry report
- April 2013
- by Global Data
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017 Summary Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, ...
- Industries : Pathology
- Countries : United States
Drugs and Diagnostics for Hematological Disorders: Global Markets
- $ 5 450
- Industry report
- March 2013
- by BCC Research
INTRODUCTION STUDY GOALS AND OBJECTIVES This report ?PHM116A Hematological Disorders: Drug Technologies, Diagnostics and Global Markets? provides an overview of the current and potential global market ...
- Industries : Pathology
- Countries : World, United States
Global Markets for Infectious Disease Treatments
- $ 5 450
- Industry report
- May 2013
- by BCC Research
STUDY GOALS AND OBJECTIVES Infectious diseases are one of the major causes of global morbidity and mortality. Viral, bacterial, parasitic and fungal diseases have plagued humankind for centuries, and ou ...
- Industries : Pathology
- Countries : World
Global Markets and Technologies for Pandemic Control
- $ 5 450
- Industry report
- March 2013
- by BCC Research
REPORT SCOPE INTRODUCTION REASONS FOR DOING THE STUDY The spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza strains and antibiotic-resistant organisms have put healthcare ...
- Industries : Pathology
- Countries : World
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis ...
- Industries : Pathology
- Countries : United Kingdom
Consensus Outlook: Prostate Cancer - Competition intensifies in race to the top
- $ 4 995
- Industry report
- April 2013
- by Firstword Pharma
Introduction Charting the Future Prostate Cancer Market Landscape The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals ...
- Industries : Pathology
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and ...
- Industries : Pathology
- Countries : Germany
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - France Drug Forecast and ...
- Industries : Pathology
- Countries : France
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market ...
- Industries : Pathology
- Countries : United States
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain ...
- Industries : Pathology
- Countries : Spain
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - France ...
- Industries : Pathology
- Countries : France
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy ...
- Industries : Pathology
- Countries : Italy
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - ...
- Industries : Pathology
- Countries : Germany
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) ...
- Industries : Pathology
- Countries : United States
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan ...
- Industries : Pathology
- Countries : Japan
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) ...
- Industries : Pathology
- Countries : United Kingdom
Singapore Post-traumatic Stress Disorder, 15-29 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Singapore
Canada Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Canada
South Korea Protein-energy Malnutrition, 15-29 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : South Korea
France Respiratory Diseases, 30-44 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : France
United States Protein-energy Malnutrition, 70+ Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : United States
United States Respiratory Infections, 70+ Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : United States
France Protein-energy Malnutrition, 70+ Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : France
Canada Respiratory Infections, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Canada
Brazil Protein-energy Malnutrition, 70+ Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : Brazil
South Korea Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : South Korea
» Download Public Reports
About 12 000 reports
Company Report: Pathology in The United States and Ireland for Year 2013
- Company report
- May 2013
- 5 pages
- by Corporation
... Involved, even indirectly, with an important therapeutic area that addresses the needs of millions of patients who suffer from respiratory disease is particularly meaningful to all of us at elan." Relvar ...
Pharmaceutical Business Analysis
May 2013U.s. Pharmaceutical Industry
May 2013The Swazi Pharmaceutical Industry
May 2013» Read our Company Profiles
About 200 CompaniesGlaxoSmithKline P.L.C.
United StatesNovartis Inc.
SwitzerlandGlaxoSmithKline PLC
United KingdomEli Lilly and Co.
United StatesLilly and Co.
United StatesReportlinker.com © Copyright 2013. All rights reserved.
